Clinical Trials Browser

Phase 1 × Recurrence × quizartinib × Clear all

Recurrence, Leukemia, Myeloid, Acute

NCT01411267 2022-04-04

AC220 for Children With Relapsed/Refractory ALL or AML

Phase 1 Completed

24 enrolled 14 charts

LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00462761 2020-05-11

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status

Phase 1 Completed

76 enrolled 12 charts

MyeloidOther hematologic neoplasm

Aortic aneurysm, familial thoracic 4, Leukemia, Erythroblastic, Acute, Leukemia, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Clinical Trials

Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)

AC220 for Children With Relapsed/Refractory ALL or AML

A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status